2022 the Japanese Society of Medical Oncology Annual Meeting

Presentation information

Print

Oral Session

[O19] Oral Session 19　Translational Research / Clinical Pharmacology
【E】

Sat. Feb 19, 2022 8:20 AM - 9:50 AM Room 13 (Gold Room, B2F, The Prince Kyoto Takaragaike)

Chair：Yuichi Ando（Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital），Yataro Daigo（Department of Medical Oncology and Cancer Center / Center for Antibody and Vaccine Therapy, Institute of Medical Science, Shiga University of Medical Science / The University of Tokyo）
Discussant：Shunsuke Kondo（Department of Experimental Therapeutics, National Cancer Center Hospital）

[O19-4] Outcomes in Japanese patients with TMB-high and non-TMB-high solid tumors treated with pembrolizumab: KEYNOTE-158

○Shunji Takahashi1, Nobumasa Mizuno2, Kosei Hasegawa3, Koji Matsumoto4, Shirong Han5, Tsutomu Takatsuki6, Fan Jin7, Kazuhiko Nakagawa8 (1.Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 2.Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan, 3.Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan, 4.Division of Medical Oncology, Hyogo Cancer Center, Hyogo, Japan, 5.Biostatistics and Research Decision Sciences, MSD K.K, Tokyo, Japan, 6.Clinical Development, MSD K.K, Tokyo, Japan, 7.Clinical Development, Merck & Co., Inc., Kenilworth, NJ, USA, 8.Department of Medical Oncology, Kindai University Hospital, Osaka, Japan)

Abstract password authentication.
The password can be found on page 27 of the program book.

Password